Interleukin-8 and interleukin-17 for cancer

Cancer Investigation

Volumn 32, Issue 5, 2014, Pages 197-205

  Zarogoulidis, Paul ^a   Katsikogianni, Fotini ^b   Tsiouda, Theodora ^c   Sakkas, Antonios ^d   Katsikogiannis, Nikolaos ^b   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^c Theageneio Anticancer Hospital   (Greece)

^d G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Cancer; Immunomodulation; Interleukin 17; Interleukin 8

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 17; INTERLEUKIN 8; TUMOR MARKER; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE EXACERBATION; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; LIVER CELL CARCINOMA; LUNG CANCER; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

HUMANS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899741888     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.898156     Document Type: Review

References (69)

1. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12(4):375-391
2. Carpagnano GE, Palladino GP, Lacedonia D, Koutelou A, Orlando S, Foschino-Barbaro MP. Neutrophilic airways inflammation in lung cancer: The role of exhaled LTB-4 and IL-8.BMC Cancer 2011;11:226
3. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67(14):6854-6862
4. Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G, Del Bufalo D. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer 2009;45(14):2618-2627
5. Cheng D, Kong H, Li Y. Prognostic value of interleukin-8 and MMP-9 in nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2014;271(3):503-509
6. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 2007;56(1):25-33
7. Yu J,Ren X, Chen Y, Liu P,Wei X, Li H, Ying G, Chen K, Winkler H, Hao X. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. PLoS One 2013;8(2):e56069
8. KassimSK, El-Salahy EM, Fayed ST, Helal SA, HelalT,AzzamEel D, Khalifa A. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004;37(5):363-369
9. Mayerhofer K, Bodner K, Bodner-Adler B, Schindl M, Kaider A, Hefler L, Zeillinger R, Leodolter S, Joura EA, Kainz C. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer 2001;91(2):388-393
10. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14(21):6735-6741
11. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010;16(15):3875-3886
12. Browne A, Sriraksa R,Guney T, RamaN,VanNoorden S, Curry E, GabraH, StronachE, El-BahrawyM. Differential expressionof IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine 2013;64(1):413-421
13. Li Z, Lin SX, Liang YJ, Zong YS. [Effect of macrophage migration inhibitory factor (MIF) on expression of MMP-2,MMP-9,and IL-8 in nasopharyngeal carcinoma cell strains]. Ai Zheng 2004;23(2):130-135
14. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012;59(1):145-155
15. Chen Y, Chen L, Li JY,Mukaida N,Wang Q, Yang C, YinWJ, Zeng XH, Jin W, Shao ZM. ERbeta and PEA3 co-Activate IL-8 expression and promote the invasion of breast cancer cells. Cancer Biol Ther 2011;11(5):497-511
16. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825(1):29-36
17. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6(5):2104-2119
18. Kitadai Y, Haruma K,Mukaida N, Ohmoto Y,Matsutani N, Yasui W, Yamamoto S, Sumii K, Kajiyama G, Fidler IJ, Tahara E. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 2000;6(7):2735-2740
19. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 andTh17 Cells. Annu Rev Immunol 2009;27:485-517
20. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 2013;25(12):2335-2347
21. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21(4):467-476
22. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: Friend or foe?. Curr Opin Investig Drugs 2009;10(6):543-549
23. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14(2):155-174
24. Amedei A,Munari F, Bella CD, Niccolai E, Benagiano M, Bencini L, Cianchi F, Farsi M, Emmi G, Zanotti G, de Bernard M, Kundu M, DElios MM. Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drivesTh17 inflammation in gastric adenocarcinoma. Intern Emerg Med 2012 (Epub ahead of print
25. Straus DS. TNFalpha and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer 2013;12:78
26. Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J, Liu J. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res 2013;352(2):351-359
27. Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, Cai XY, Zhou J, Cheng YF, Fan J, Qiu SJ. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res 2013;32:3
28. Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y, Xu J, Rao H, Chen S, Zhang L, Zheng L. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother 2013;62(10):1575-1585
29. Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 2012;148(2):144-150
30. Cui X, Xu Z, Zhao Z, SuiD, Ren X, HuangQ,Qin J, Hao L,Wang Z, Shen L, Lin S. Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci 2013;9(2):134-141
31. Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol 2009;70(7):547-551
32. Liu XK, Lin X, Gaffen SL. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J Biol Chem 2004;279(50):52762-52771
33. Benchetrit F, Ciree A, Vives V,WarnierG,Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, FridmanWH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99(6):2114-2121
34. Zhang B, Rong G, WeiH, ZhangM, Bi J, Ma L, Xue X,Wei G, Liu X, Fang G. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008;374(3):533-537
35. Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M, Salifoglou A. Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-? . PLoS One 2013;8(9):e73616
36. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175(9):6177-6189
37. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010;69(3):348-354
38. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z, Zhu B. Role of interleukin-17 in lymphangiogenesis in nonsmall-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010;101(11):2384-2390
39. Zhang GQ, Han F, Fang XZ, Ma XM. CD4+, IL17 and Foxp3 expression in Different pTNM stages of operable non-small cell lung cancer and effects on Disease prognosis. Asian Pac J Cancer Prev 2012;13(8):3955-3960
40. Wu J, Du J, Liu L, Li Q, Rong W, Wang L, Wang Y, Zang M, Wu Z, Zhang Y, Qu C. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One 2012;7(12):e50035
41. Klimatsidas M, Anastasiadis K, Foroulis C, Tossios P, Bisiklis A, Papakonstantinou C, Rammos K. Elevated levels of anti inflammatory IL-10 and pro inflammatory IL-17 in malignant pleural effusions. J Cardiothorac Surg 2012;7:104
42. Zarogoulidis P, Yarmus L, Darwiche K, Walter R, Huang H, Li Z, Zaric B, Tsakiridis K, Zarogoulidis K. Interleukin-6 cytokine: Amultifunctional glycoprotein for cancer. Immunome Res 2013;9(62):16535
43. Zarogoulidis P, Yarmus L, Zarogoulidis K. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer.Ther Deliv 2013;4(10):1221-1223
44. Shiau MY, Fan LC, Yang SC, Tsao CH, Lee H, Cheng YW, Lai LC, Chang YH. Human papillomavirus up-regulatesMMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. PLoS One 2013;8(1):e54423
45. Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 2013;15(4):210
46. Park SH, Kim JH, Lee DH, Kang JW, Song HH, Oh SR, Yoon DY. Luteolin 8-C-beta-fucopyranoside inhibits invasion and suppresses TPA-induced MMP-9 and IL-8 via ERK/AP-1 and ERK/NF-kappaB signaling in MCF-7 breast cancer cells. Biochimie 2013;95(11):2082-2090
47. Bhat IA, Pandith AA, Bhat BA, Naykoo NA, Qasim I, Rasool R, Aziz SA, Shah ZA. Lack of association of a common polymorphism in the 3 -UTR of interleukin 8 with non small cell lung cancer in Kashmir. Asian Pac J Cancer Prev 2013;14(7):4403-4408
48. Rafrafi A, Chahed B, Kaabachi S, KaabachiW,MaalmiH,HamzaouiK, Sassi FH.Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: A case control study. Hum Immunol 2013;74(10):1368-1374
49. Lattanzio L, Tonissi F,Torta I, Gianello L, RussiE,MilanoG,Merlano M, Lo Nigro C. Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs 2013;31(5):1107-1114
50. Yamada S, Kato S, Matsuhisa T, Makonkawkeyoon L, Yoshida M, Chakrabandhu T, Lertprasertsuk N, Suttharat P, Chakrabandhu B, Nishiumi S, Chongraksut W, Azuma T. Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. World J Gastroenterol 2013;19(19):2941-2949
51. Albulescu R, Codrici E, Popescu ID,Mihai S, Necula LG, Petrescu D, TeodoruM, Tanase CP. Cytokine patterns in brain tumour progression. Mediators Inflamm 2013;2013:979748
52. Jo SY, Wang PI, N?r JE, Bellile EL, Zhang Z, Worden FP, Srinivasan A, Mukherji SK. CT Perfusion Can Predict Overexpression of CXCL8 (Interleukin-8) in Head and Neck Squamous Cell Carcinoma. AJNR Am J Neuroradiol 2013;34(12):2338-2342
53. Desai S, Laskar S, Pandey BN. Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. Cell Signal 2013;25(9):1780-1791
54. Gyanchandani R, Sano D, Ortega Alves MV, Klein JD, Knapick BA, Oh S, Myers JN, Kim S. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma. Oral Oncol 2013;49(8):761-770
55. He J, Qian X, Carpenter R, Xu Q, Wang L, Qi Y, Wang ZX, Liu LZ, Jiang BH. Repression of miR-143 mediates Cr (VI)-induced tumor angiogenesis via IGF-IR/IRS1/ERK/IL-8 pathway. Toxicol Sci 2013;134(1):26-38
56. Hsiao YP, Yang JH, Wu WJ, Lin MH, Sheu GT. E6 and E7 of human papillomavirus type 18 and UVB irradiation corporately regulate interleukin-6 and interleukin-8 expressions in basal cell carcinoma. Exp Dermatol 2013;22(10):672-674
57. Hsu WL, Chiu SJ, Tsai YT, Chang CM, Wang JY, Wang ET, Hou MF, Huang CY, Sheu JH, Chang WC. A soft coral natural product, 11-episinulariolide acetate, inhibits gene expression of cyclooxygenase-2 and interleukin-8 through attenuation of calcium signaling. Molecules 2013;18(6):7023-7034
58. Cesaratto L, Codarin E, Vascotto C, Leonardi A, Kelley MR, TiribelliC, TellG. Specific inhibition of the redox activity of ape1/ref-1 by e3330 blocks tnf-Alpha-induced activation of IL-8 production in liver cancer cell lines. PLoS One 2013;8(8):e70909
59. Rafiei A, Hosseini V, Janbabai G, Ghorbani A, Ajami A, Farzmandfar T, Azizi MD, Gilbreath JJ,Merrell DS. Polymorphism in the interleukin-17A promoter contributes to gastric cancer.World J Gastroenterol 2013;19(34):5693-5699
60. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol 2013;8:40
61. Li L, Boussiotis VA. The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clin Immunol 2013;148(2):246-253
62. Olsson Akefeldt S, Maisse C, Belot A, Mazzorana M, Salvatore G, Bissay N, Jurdic P, AricòM, Rabourdin-Combe C, Henter JI, Delprat C. Chemoresistance of human monocyte-derived dendritic cells is regulated by IL-17A. PLoS One 2013;8(2):e56865
63. Hayata K, Iwahashi M, Ojima T, Katsuda M, Iida T, Nakamori M, Ueda K, Nakamura M, Miyazawa M, Tsuji T, Yamaue H. Inhibition of IL-17A in tumormicroenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS One 2013;8(1):e53131
64. Jordan-Williams KL, Poston S, Taparowsky EJ. BATF regulates the development and function of IL-17 producing iNKT cells. BMC Immunol 2013;14:16
65. Droeser RA, Guth U, Eppenberger-Castori S, Stadlmann S, Hirt C, Terracciano L, Singer G. High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma. J Cancer Res Clin Oncol 2013;139(8):1295-1302
66. Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH. Interleukin-17- producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 2013;63(2):225-233
67. Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012;30(6):475-477
68. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-1674
69. Leitner JM,Mayr FB, Firbas C, Spiel AO, Steinlechner B, Novellini R, Jilma B. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation During endotoxemia. Int J Immunopathol Pharmacol 2007;20(1):25-36